stockrowHarmony Biosciences Holdings, Inc.
HRMY Healthcare Biotechnology
Harmony Biosciences Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $868.5 million, up 21.5% from fiscal 2024.
- Revenue
- +12.3%
- EPS
- −6.24%
- Free cash flow
- −29.4%
- Total debt
- −11.5%
Quarter to September 2026, against a year earlier
Follow HRMY
Alert me
Harmony Biosciences Holdings, Inc. (HRMY) Return on equity
Harmony Biosciences Holdings, Inc.'s return on equity over the twelve months to 30 September 2026 was 18.7%, down 2.0 percentage points from fiscal 2025 (20.8%). Over the past ten years it has ranged from 20.8% (fiscal 2025) to 61.6% (fiscal 2022) — the current reading is the lowest in ten years. That is above the Biotechnology industry median of −52.0% and above the Healthcare sector median of −26.0%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 20.8% | (5.09) |
| FY2024 | 25.8% | (3.79) |
| FY2023 | 29.6% | (31.95) |
| FY2022 | 61.6% | 37.19 |
| FY2021 | 24.4% | (14.82) |
| FY2020 | 39.2% | (17.05) |
| FY2019 | 56.3% | 35.20 |
| FY2018 | 21.1% | — |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| HRMY Harmony Biosciences Holdings, Inc. | 18.7% |
| TRAX First Tracks Biotherapeutics, Inc. compare | 0.00% |
| MESO Mesoblast Limited compare | 0.00% |
| SRPT Sarepta Therapeutics, Inc. compare | −8.05% |
| FTRE Fortrea Holdings Inc. compare | −12.3% |
| TRVI Trevi Therapeutics, Inc. compare | −19.7% |
| VIR Vir Biotechnology, Inc. compare | −21.8% |
| MAZE Maze Therapeutics, Inc. compare | −37.4% |
| REPL Replimune Group, Inc. compare | −115.8% |
| Biotechnology industry median | −52.0% |
| Healthcare sector median | −26.0% |
| Market median | 1.01% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)